Discovery of novel drugs that are able to prevent angiogenesis is a fast growing branch of
cancer research. Current approaches to cancer chemotherapy include the use of alkylating agents,
antimetabolites, antitumor antibiotics, platinum analogs and drugs derived from natural compounds.
However, most of the currently used chemotherapeutic drugs have adverse side effects on normal
healthy cells. In addition to the classical targets of cancer chemotherapy, prevention of angiogenesis
through the regulation of indigenous angiogenic factors is a leading approach of developing selective novel anticancer
drugs. Because of their low toxicity, there is increasing interest in exploring specific dietary phytochemicals as possible
antiangiogenic agents. In this mini-review, selected flavonoids (e.g., apigenin, luteolin, quercetin and epigallocatechin-3-
gallate, which are a group of plant polyphenols) that are able to regulate angiogenesis in in vitro and in vivo systems are
discussed in the light of their potential to be exploited as novel anticancer drugs.